DLBCL

News
Card image cap

ADC Therapeutics sets terms for $125m IPO

Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop its pipeline of antibody-drug conjugate drugs as they head towards regulatory review.